As GSK gears up for high-stakes daprodustat panel review, FDA flags some safety concerns

As an FDA expert panel gears up to review GSK’s oral anemia prospect daprodustat, the agency released a briefing document that outlines safety concerns for consideration. This week's adcomm could be pivotal for the drug's approval chances, given safety issues scuppered rival drugs from AstraZeneca, plus Akebia and Otsuka.